Leuprolide acetate

(Lupron depot®)

Lupron depot®

Drug updated on 11/4/2024

Dosage FormInjection (intramuscular; 7.5 mg, 22.5 mg, 30 mg, and 45 mg)
Drug ClassGonadotropin-releasing hormone agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of advanced prostate cancer.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • The reviewed studies did not provide direct evidence on the clinical effectiveness of leuprolide acetate or other GnRH (gonadotropin-releasing hormone) agonists in prostate cancer treatment; instead, they focused on cardiovascular safety and rare adverse events, particularly comparing GnRH agonists to antagonists.
  • Subgroup analyses were not detailed in terms of effectiveness outcomes. The only notable subgroup concern mentioned was an elevated risk of pituitary apoplexy in older prostate cancer patients with pre-existing pituitary adenomas following GnRH agonist administration.
  • GnRH antagonists, such as degarelix and relugolix, presented a significantly lower risk of cardiovascular adverse events compared to GnRH agonists, with pooled risk ratios indicating reduced occurrences of adverse cardiovascular events (0.57; 95% CI: 0.39-0.81), cardiovascular death (0.49; 95% CI: 0.25-0.96), and all-cause mortality (0.48; 95% CI: 0.28-0.83).
  • Pituitary apoplexy was identified as a rare but serious adverse event following GnRH agonist administration, particularly in prostate cancer patients with pre-existing pituitary adenomas. This condition manifested with symptoms such as headache (100%) and ophthalmoplegia (85.7%), with a median onset of 5 hours post-administration, and required surgical intervention in 71.4% of cases.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Lupron depot (leuprolide acetate) Prescribing Information.2024AbbVie Inc., North Chicago, IL

Systematic Reviews / Meta-Analyses